<DOC>
	<DOCNO>NCT02863068</DOCNO>
	<brief_summary>The investigator propose Phase II study , prospective placebo control , topical cream contain sodium nitrite compare current standard care . Sodium nitrite local donor nitric oxide , know improve blood flow decrease bacterial load ulcer bed . The primary objective evaluate safety topical sodium nitrite cream treatment patient sickle cell disease chronic leg ulcer determine effectiveness accelerate heal process decrease pain associate ulceration . Potential benefit durable resolution improvement leg ulcer associate pain . Possible side effect include decrease blood pressure methemoglobinemia , secondary sodium nitrite absorption ulcerate skin .</brief_summary>
	<brief_title>Topical Sodium Nitrite Sickle Cell Disease Leg Ulcers</brief_title>
	<detailed_description>Chronic leg ulcer complication many blood disorder sickle cell disease , thalassemia , red blood cell disorder . In disorder , red blood cell break early normal , researcher suspect may cause contribute development leg ulcer ; however , exact cause unknown , current therapy effective . Researchers interested determine research cream make sodium nitrite , substance know increase blood flow dilate blood vessel , may speed heal skin ulcer . Investigators plan enroll fifty patient sickle cell disease randomize treat twice week sodium nitrite cream placebo ten week . The following event compare treatment placebo arm : ) change blood pressure ; b ) change pulse oximetry ; c ) change methemoglobin level ; ) adverse event ; e ) rate SCD related complication ; f ) change biomarkers inflammation laboratory data complete blood count chemistry . In order determine topical sodium nitrite accelerate wound heal decrease pain wound site compare placebo patient receive similar level wound care , investigator ) accurately measure photograph ulcer baseline , two week run-in period predefined time point study compare treatment arm placebo ; b ) pain score wind site record compare two group , c ) Investigators calculate opioid intake two arm ) quality life measure end trial</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<criteria>Subjects must diagnosis sickle cell disease ( SS , SC , SÃŸthalassemia , SD , SOArab ) . Have one ulcer one leg foot . Total surface area leg ulcer ( ) receive treatment must large 100 cm2 . No history congenital methemoglobinemia . Have document normal G6PD activity . Exposure therapeutic nitric oxide , Larginine , nitroprusside nitroglycerine within past 1 week . Subjects present clinically diagnose bacterial infection ( e.g. , osteomyelitis , pneumonia , sepsis meningitis ) . Subjects preexist methemoglobinemia ( 2.5 % ) Patients currently enrol investigational drug study ( include observational natural history protocol ) . Use PDE5 inhibitor , sildenafil , 4 day prior screen . Pregnant woman ( urine serum HCG + ) nursing mother . The following list drug agent may cause methemoglobinemia avoid study : Anesthetics ( local ) : Benzocaine , procaine , prilocaine , Anbesol , Orajel Antimalarials : chloroquine , primaquine , quinacrine Aniline dye Chlorates Dapsone Diarylsulfonylureas Doxorubicin Metoclopramide Nitric nitrous oxide Nitrobenzenes ( shoe floor polish paint solvent ) Nitroethane ( artificial nail remover , propellant , fuel additive ) Nitrofurantoin ( furadantin ) Pyridium ( phenazopyridine ) Phenacetin ( acetaminophen ) Phenylhydrazine Rasburicase Sulfonamides ( sulfacetamide , sulfamethoxazole , sulfanilamide , sulfapyridine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Sickle cell disease</keyword>
	<keyword>sodium nitrite</keyword>
	<keyword>wound healing</keyword>
	<keyword>Ulcer</keyword>
</DOC>